clinical trial · NCT05469464
Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)
Atopic DermatitisSkin DiseasesOrismilast modified release tabletsPlacebo
brief summary
This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe atopic dermatitis. The purpose of the study is to assess the effect of orismilast modified release in moderate-to-severe atopic dermatitis and assess the safety aspects of these 3 different doses. The patients will receive an oral treatment of either orismilast modified release tablets or placebo tablets 2 times a day for 16 weeks.
started
Jul 11, 2022
primary completion
Jan 23, 2024
completion
Feb 15, 2024
last updated
Mar 7, 2025
official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of Orismilast in Adults With Moderate to Severe Atopic Dermatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol